# Elaine M. Hylek

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/elaine-m-hylek/

## Facts

| Field | Value |
| --- | --- |
| Citations | 59,882 |
| Field | Atrial Fibrillation Management and Outcomes |
| h-index | 96 |
| i10-index | 229 |
| Last Known Institution | Boston University |
| OpenAlex ID | https://openalex.org/A5080799947 |
| ORCID iD | https://orcid.org/0000-0001-8263-8304 |
| Works | 401 |

## Researcher papers

Showing 12 of 15.

- [Apixaban versus Warfarin in Patients with Atrial Fibrillation](https://scholariq.org/papers/apixaban-versus-warfarin-in-patients-with-atrial-fibrillation/)
- [Prevalence of Diagnosed Atrial Fibrillation in Adults](https://scholariq.org/papers/prevalence-of-diagnosed-atrial-fibrillation-in-adults/)
- [2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation](https://scholariq.org/papers/2017-hrs-ehra-ecas-aphrs-solaece-expert-consensus-statement-on-catheter-and/)
- [Idarucizumab for Dabigatran Reversal](https://scholariq.org/papers/idarucizumab-for-dabigatran-reversal/)
- [2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation](https://scholariq.org/papers/2017-hrs-ehra-ecas-aphrs-solaece-expert-consensus-statement-on-catheter-and-3/)
- [Idarucizumab for Dabigatran Reversal — Full Cohort Analysis](https://scholariq.org/papers/idarucizumab-for-dabigatran-reversal-full-cohort-analysis/)
- [Antithrombotic Therapy for Atrial Fibrillation](https://scholariq.org/papers/antithrombotic-therapy-for-atrial-fibrillation/)
- [2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary](https://scholariq.org/papers/2017-hrs-ehra-ecas-aphrs-solaece-expert-consensus-statement-on-catheter-and-2/)
- [Advanced Age, Anticoagulation Intensity, and Risk for Intracranial Hemorrhage among Patients Taking Warfarin for Atrial Fibrillation](https://scholariq.org/papers/advanced-age-anticoagulation-intensity-and-risk-for-intracranial-hemorrhage/)
- [Death and Disability from Warfarin-Associated Intracranial and Extracranial Hemorrhages](https://scholariq.org/papers/death-and-disability-from-warfarin-associated-intracranial-and-extracranial/)
- [2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary](https://scholariq.org/papers/2017-hrs-ehra-ecas-aphrs-solaece-expert-consensus-statement-on-catheter-and-4/)
- [The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study](https://scholariq.org/papers/the-novel-biomarker-based-abc-age-biomarkers-clinical-history-bleeding-risk/)

## Researcher topics

- [Atrial Fibrillation Management and Outcomes](https://scholariq.org/topics/atrial-fibrillation-management-and-outcomes/)
- [Venous Thromboembolism Diagnosis and Management](https://scholariq.org/topics/venous-thromboembolism-diagnosis-and-management-2/)
- [Antiplatelet Therapy and Cardiovascular Diseases](https://scholariq.org/topics/antiplatelet-therapy-and-cardiovascular-diseases/)
- [Acute Ischemic Stroke Management](https://scholariq.org/topics/acute-ischemic-stroke-management/)
- [Cardiac Arrhythmias and Treatments](https://scholariq.org/topics/cardiac-arrhythmias-and-treatments/)

## Researcher university

- [Boston University](https://scholariq.org/institutions/boston-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.